Heartbeam rises after FDA clears its cable‑free ECG software

Shares of heart monitor maker Heartbeam BEAT.O soar 67.6% to $1.34 premarket

HeartBeam says the U.S. FDA has cleared its software that lets a small, cable‑free device record a detailed heart rhythm test at home, overturning an earlier rejection

The software turns signals from HeartBeam's credit‑card sized gadget into a 12‑lead electrocardiogram (ECG), the same format doctors use in clinics and hospitals to study heart rhythm

A reading taken by the patient is sent for review to an on‑call heart specialist, the company says

BEAT plans a limited U.S. launch in early 2026 with a small group of concierge and preventive cardiology practices that have already shown interest

As of last close, BEAT stock was down ~65% YTD